id int64 | supply_chain string | facility_id string | facility_type string | region_type string | product_name string | drug_class string | treatment_line string | dosage_form string | reference_price_usd float64 | WHO_prequalified int64 | registered_product int64 | from_pooled_procurement int64 | manufacturer_origin string | year int64 | quarter int64 | quality_test_result string | sf_classification string | failure_mode string | API_content_pct float64 | viral_suppression_impact int64 | resistance_emergence int64 | treatment_interruption int64 | patient_population string | on_ART_duration_months int64 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | national_programme | ARV_0018 | community_health_post | rural | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 0 | 1 | 0 | Europe | 2,024 | 4 | pass | compliant | not_applicable | 97.3 | 0 | 0 | 0 | adult_female | 39 |
2 | national_programme | ARV_0156 | private_pharmacy | peri_urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 1 | 1 | 1 | China | 2,023 | 3 | pass | compliant | not_applicable | 97.6 | 0 | 0 | 0 | adolescent | 44 |
3 | national_programme | ARV_0135 | ART_clinic | peri_urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 1 | 1 | 0 | local_SSA | 2,024 | 4 | pass | compliant | not_applicable | 97.4 | 0 | 0 | 0 | adult_female | 23 |
4 | national_programme | ARV_0093 | community_health_post | urban | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 0 | 1 | 0 | local_SSA | 2,022 | 1 | pass | compliant | not_applicable | 99.5 | 0 | 0 | 0 | adult_female | 10 |
5 | national_programme | ARV_0048 | ART_clinic | urban | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 1 | 1 | 0 | local_SSA | 2,024 | 3 | pass | compliant | not_applicable | 97.7 | 0 | 0 | 0 | adult_male | 4 |
6 | national_programme | ARV_0088 | community_health_post | peri_urban | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 0 | 1 | 0 | South_Africa | 2,022 | 3 | fail | substandard | insufficient_API | 49.5 | 0 | 0 | 1 | adult_male | 91 |
7 | national_programme | ARV_0087 | private_clinic | rural | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 0 | 1 | 0 | India | 2,020 | 3 | pass | compliant | not_applicable | 96.6 | 0 | 0 | 0 | adult_female | 13 |
8 | national_programme | ARV_0180 | ART_clinic | peri_urban | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 1 | 1 | 1 | South_Africa | 2,022 | 3 | pass | compliant | not_applicable | 96.4 | 0 | 0 | 0 | adolescent | 36 |
9 | national_programme | ARV_0099 | district_hospital | rural | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 0 | 1 | 1 | India | 2,020 | 3 | pass | compliant | not_applicable | 100.7 | 0 | 0 | 0 | adult_male | 11 |
10 | national_programme | ARV_0161 | ART_clinic | rural | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 0 | 1 | 1 | South_Africa | 2,023 | 3 | pass | compliant | not_applicable | 97 | 0 | 0 | 0 | adult_female | 2 |
11 | national_programme | ARV_0036 | district_hospital | urban | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 1 | 1 | 1 | unknown | 2,023 | 2 | pass | compliant | not_applicable | 100.3 | 0 | 0 | 0 | adult_male | 195 |
12 | national_programme | ARV_0084 | private_pharmacy | urban | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 1 | 1 | 0 | South_Africa | 2,023 | 2 | pass | compliant | not_applicable | 97.4 | 0 | 0 | 0 | adult_female | 22 |
13 | national_programme | ARV_0057 | private_pharmacy | rural | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 1 | 1 | 1 | local_SSA | 2,022 | 1 | pass | compliant | not_applicable | 102.5 | 0 | 0 | 0 | paediatric | 6 |
14 | national_programme | ARV_0123 | district_hospital | urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 0 | 1 | 0 | China | 2,022 | 4 | pass | compliant | not_applicable | 99.8 | 0 | 0 | 0 | adult_female | 20 |
15 | national_programme | ARV_0198 | ART_clinic | urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 1 | 0 | 0 | local_SSA | 2,024 | 4 | pass | compliant | not_applicable | 99.6 | 0 | 0 | 0 | adult_female | 81 |
16 | national_programme | ARV_0067 | district_hospital | urban | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 0 | 1 | 0 | India | 2,021 | 3 | pass | compliant | not_applicable | 98.6 | 0 | 0 | 0 | adult_male | 9 |
17 | national_programme | ARV_0144 | ART_clinic | urban | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 0 | 0 | 0 | India | 2,020 | 4 | pass | compliant | not_applicable | 99.2 | 0 | 0 | 0 | pregnant_woman | 3 |
18 | national_programme | ARV_0060 | private_clinic | peri_urban | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 1 | 1 | 0 | local_SSA | 2,021 | 3 | pass | compliant | not_applicable | 100 | 0 | 0 | 0 | adult_female | 23 |
19 | national_programme | ARV_0027 | private_clinic | rural | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 1 | 0 | 1 | South_Africa | 2,023 | 2 | pass | compliant | not_applicable | 99.2 | 0 | 0 | 0 | adult_female | 72 |
20 | national_programme | ARV_0034 | informal_source | rural | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 1 | 1 | 1 | India | 2,024 | 3 | pass | compliant | not_applicable | 94.7 | 0 | 0 | 0 | adult_female | 89 |
21 | national_programme | ARV_0186 | private_clinic | peri_urban | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 1 | 1 | 0 | unknown | 2,023 | 4 | pass | compliant | not_applicable | 96.4 | 0 | 0 | 0 | pregnant_woman | 61 |
22 | national_programme | ARV_0191 | ART_clinic | peri_urban | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 1 | 0 | 1 | India | 2,024 | 1 | pass | compliant | not_applicable | 98.2 | 0 | 0 | 0 | adult_male | 18 |
23 | national_programme | ARV_0108 | ART_clinic | urban | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 1 | 1 | 0 | India | 2,022 | 1 | pass | compliant | not_applicable | 99 | 0 | 0 | 0 | paediatric | 2 |
24 | national_programme | ARV_0099 | district_hospital | urban | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 0 | 1 | 1 | India | 2,023 | 1 | pass | compliant | not_applicable | 101.4 | 0 | 0 | 0 | adult_male | 96 |
25 | national_programme | ARV_0138 | private_pharmacy | rural | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 0 | 1 | 0 | South_Africa | 2,024 | 1 | pass | compliant | not_applicable | 98.5 | 0 | 0 | 0 | adult_female | 35 |
26 | national_programme | ARV_0166 | district_hospital | peri_urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 1 | 1 | 1 | India | 2,021 | 2 | pass | compliant | not_applicable | 100.7 | 0 | 0 | 0 | adult_female | 20 |
27 | national_programme | ARV_0037 | district_hospital | rural | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 0 | 1 | 1 | India | 2,024 | 3 | pass | compliant | not_applicable | 100.7 | 0 | 0 | 0 | adult_female | 5 |
28 | national_programme | ARV_0015 | private_pharmacy | urban | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 0 | 0 | 1 | South_Africa | 2,020 | 2 | pass | compliant | not_applicable | 100.5 | 0 | 0 | 0 | adolescent | 6 |
29 | national_programme | ARV_0192 | private_pharmacy | peri_urban | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 0 | 1 | 0 | India | 2,023 | 4 | pass | compliant | not_applicable | 99.6 | 0 | 0 | 0 | adult_female | 21 |
30 | national_programme | ARV_0095 | community_health_post | rural | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 0 | 1 | 0 | unknown | 2,021 | 2 | fail | falsified | counterfeit_packaging | 93.5 | 0 | 0 | 0 | adult_female | 34 |
31 | national_programme | ARV_0163 | district_hospital | urban | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 1 | 1 | 1 | unknown | 2,022 | 4 | pass | compliant | not_applicable | 102 | 0 | 0 | 0 | adult_female | 156 |
32 | national_programme | ARV_0072 | community_health_post | urban | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 0 | 1 | 0 | India | 2,024 | 4 | pass | compliant | not_applicable | 95 | 0 | 0 | 0 | adult_female | 94 |
33 | national_programme | ARV_0109 | community_health_post | rural | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 1 | 1 | 1 | India | 2,024 | 1 | pass | compliant | not_applicable | 96.2 | 0 | 0 | 0 | adolescent | 35 |
34 | national_programme | ARV_0137 | private_pharmacy | urban | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 0 | 1 | 0 | India | 2,024 | 2 | fail | substandard | insufficient_API | 71.6 | 1 | 0 | 0 | adult_male | 1 |
35 | national_programme | ARV_0032 | private_clinic | rural | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 1 | 0 | 1 | China | 2,024 | 1 | pass | compliant | not_applicable | 101.2 | 0 | 0 | 0 | paediatric | 3 |
36 | national_programme | ARV_0091 | ART_clinic | peri_urban | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 0 | 1 | 0 | India | 2,024 | 1 | pass | compliant | not_applicable | 98.3 | 0 | 0 | 0 | pregnant_woman | 42 |
37 | national_programme | ARV_0150 | ART_clinic | peri_urban | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 1 | 0 | 0 | India | 2,020 | 3 | pass | compliant | not_applicable | 96.9 | 0 | 0 | 0 | adult_female | 31 |
38 | national_programme | ARV_0051 | private_clinic | urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 0 | 1 | 0 | local_SSA | 2,023 | 3 | pass | compliant | not_applicable | 99.8 | 0 | 0 | 0 | adult_female | 16 |
39 | national_programme | ARV_0182 | ART_clinic | urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 1 | 1 | 1 | South_Africa | 2,023 | 2 | pass | compliant | not_applicable | 97.3 | 0 | 0 | 0 | adult_male | 34 |
40 | national_programme | ARV_0120 | ART_clinic | peri_urban | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 1 | 1 | 0 | South_Africa | 2,024 | 2 | pass | compliant | not_applicable | 99.4 | 0 | 0 | 0 | adult_female | 112 |
41 | national_programme | ARV_0069 | community_health_post | peri_urban | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 1 | 1 | 0 | unknown | 2,024 | 3 | pass | compliant | not_applicable | 98.7 | 0 | 0 | 0 | paediatric | 19 |
42 | national_programme | ARV_0104 | community_health_post | urban | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 1 | 0 | 1 | India | 2,022 | 4 | pass | compliant | not_applicable | 100.9 | 0 | 0 | 0 | pregnant_woman | 1 |
43 | national_programme | ARV_0087 | private_pharmacy | urban | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 1 | 1 | 1 | India | 2,024 | 4 | pass | compliant | not_applicable | 99.9 | 0 | 0 | 0 | adult_female | 69 |
44 | national_programme | ARV_0029 | district_hospital | peri_urban | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 1 | 1 | 0 | India | 2,021 | 3 | pass | compliant | not_applicable | 102.3 | 0 | 0 | 0 | adult_female | 21 |
45 | national_programme | ARV_0160 | ART_clinic | peri_urban | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 1 | 1 | 0 | India | 2,023 | 4 | pass | compliant | not_applicable | 97.1 | 0 | 0 | 0 | adolescent | 1 |
46 | national_programme | ARV_0126 | district_hospital | peri_urban | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 0 | 1 | 1 | India | 2,024 | 1 | pass | compliant | not_applicable | 98.6 | 0 | 0 | 0 | pregnant_woman | 21 |
47 | national_programme | ARV_0123 | district_hospital | peri_urban | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 1 | 0 | 1 | Europe | 2,024 | 1 | pass | compliant | not_applicable | 98.4 | 0 | 0 | 0 | adult_female | 70 |
48 | national_programme | ARV_0077 | community_health_post | peri_urban | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 1 | 1 | 0 | South_Africa | 2,021 | 2 | pass | compliant | not_applicable | 100.5 | 0 | 0 | 0 | adult_male | 149 |
49 | national_programme | ARV_0138 | district_hospital | peri_urban | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 1 | 1 | 0 | South_Africa | 2,024 | 2 | pass | compliant | not_applicable | 101.5 | 0 | 0 | 0 | paediatric | 36 |
50 | national_programme | ARV_0103 | informal_source | rural | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 0 | 1 | 0 | India | 2,023 | 3 | pass | compliant | not_applicable | 102.2 | 0 | 0 | 0 | adolescent | 28 |
51 | national_programme | ARV_0164 | private_pharmacy | urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 1 | 1 | 0 | India | 2,024 | 3 | pass | compliant | not_applicable | 95.5 | 0 | 0 | 0 | adult_female | 22 |
52 | national_programme | ARV_0130 | private_clinic | rural | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 0 | 0 | 1 | India | 2,020 | 1 | pass | compliant | not_applicable | 99.5 | 0 | 0 | 0 | pregnant_woman | 56 |
53 | national_programme | ARV_0002 | private_pharmacy | rural | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 1 | 1 | 0 | unknown | 2,020 | 4 | pass | compliant | not_applicable | 97.8 | 0 | 0 | 0 | adult_male | 93 |
54 | national_programme | ARV_0140 | private_clinic | urban | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 0 | 1 | 0 | India | 2,023 | 4 | pass | compliant | not_applicable | 98.4 | 0 | 0 | 0 | paediatric | 38 |
55 | national_programme | ARV_0136 | district_hospital | rural | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 0 | 0 | 1 | India | 2,021 | 1 | pass | compliant | not_applicable | 95.5 | 0 | 0 | 0 | adult_female | 23 |
56 | national_programme | ARV_0044 | ART_clinic | urban | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 1 | 1 | 1 | India | 2,023 | 2 | pass | compliant | not_applicable | 98.4 | 0 | 0 | 0 | adolescent | 18 |
57 | national_programme | ARV_0101 | district_hospital | rural | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 1 | 1 | 0 | India | 2,024 | 3 | pass | compliant | not_applicable | 99.5 | 0 | 0 | 0 | adult_male | 6 |
58 | national_programme | ARV_0060 | ART_clinic | rural | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 1 | 1 | 0 | Europe | 2,022 | 2 | pass | compliant | not_applicable | 101.5 | 0 | 0 | 0 | pregnant_woman | 27 |
59 | national_programme | ARV_0134 | private_pharmacy | urban | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 0 | 1 | 0 | unknown | 2,023 | 4 | pass | compliant | not_applicable | 100.9 | 0 | 0 | 0 | adolescent | 2 |
60 | national_programme | ARV_0059 | district_hospital | urban | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 1 | 1 | 1 | India | 2,021 | 1 | pass | compliant | not_applicable | 101.1 | 0 | 0 | 0 | pregnant_woman | 17 |
61 | national_programme | ARV_0195 | district_hospital | peri_urban | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 1 | 1 | 0 | India | 2,023 | 2 | pass | compliant | not_applicable | 95.9 | 0 | 0 | 0 | adult_female | 65 |
62 | national_programme | ARV_0093 | district_hospital | urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 1 | 1 | 0 | India | 2,022 | 4 | pass | compliant | not_applicable | 96.7 | 0 | 0 | 0 | adult_female | 24 |
63 | national_programme | ARV_0039 | ART_clinic | urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 0 | 1 | 1 | India | 2,021 | 1 | pass | compliant | not_applicable | 101 | 0 | 0 | 0 | adult_female | 90 |
64 | national_programme | ARV_0137 | ART_clinic | rural | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 0 | 1 | 0 | unknown | 2,022 | 4 | pass | compliant | not_applicable | 97 | 0 | 0 | 0 | adult_female | 17 |
65 | national_programme | ARV_0147 | district_hospital | rural | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 0 | 1 | 1 | India | 2,020 | 4 | pass | compliant | not_applicable | 95.4 | 0 | 0 | 0 | adult_male | 9 |
66 | national_programme | ARV_0132 | private_pharmacy | rural | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 1 | 0 | 0 | India | 2,021 | 3 | pass | compliant | not_applicable | 99.8 | 0 | 0 | 0 | adult_female | 51 |
67 | national_programme | ARV_0053 | ART_clinic | rural | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 0 | 1 | 0 | unknown | 2,023 | 1 | pass | compliant | not_applicable | 98.7 | 0 | 0 | 0 | adult_male | 51 |
68 | national_programme | ARV_0027 | private_clinic | rural | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 1 | 1 | 1 | unknown | 2,022 | 2 | pass | compliant | not_applicable | 96.8 | 0 | 0 | 0 | adult_female | 42 |
69 | national_programme | ARV_0106 | private_clinic | rural | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 0 | 1 | 0 | India | 2,024 | 3 | pass | compliant | not_applicable | 98 | 0 | 0 | 0 | adult_male | 40 |
70 | national_programme | ARV_0131 | private_clinic | urban | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 0 | 1 | 1 | unknown | 2,024 | 2 | pass | compliant | not_applicable | 94.8 | 0 | 0 | 0 | pregnant_woman | 55 |
71 | national_programme | ARV_0129 | community_health_post | rural | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 0 | 1 | 0 | India | 2,024 | 2 | pass | compliant | not_applicable | 97.2 | 0 | 0 | 0 | adult_male | 24 |
72 | national_programme | ARV_0086 | ART_clinic | rural | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 1 | 1 | 0 | India | 2,022 | 3 | pass | compliant | not_applicable | 100.7 | 0 | 0 | 0 | adult_female | 22 |
73 | national_programme | ARV_0115 | community_health_post | urban | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 1 | 1 | 1 | India | 2,023 | 4 | pass | compliant | not_applicable | 100.3 | 0 | 0 | 0 | adult_male | 8 |
74 | national_programme | ARV_0095 | private_pharmacy | urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 1 | 1 | 0 | India | 2,022 | 4 | pass | compliant | not_applicable | 97 | 0 | 0 | 0 | adolescent | 204 |
75 | national_programme | ARV_0135 | ART_clinic | urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 1 | 1 | 0 | unknown | 2,024 | 2 | pass | compliant | not_applicable | 96.7 | 0 | 0 | 0 | adult_male | 6 |
76 | national_programme | ARV_0188 | private_clinic | urban | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 0 | 1 | 0 | India | 2,022 | 2 | pass | compliant | not_applicable | 101.1 | 0 | 0 | 0 | adult_female | 102 |
77 | national_programme | ARV_0148 | district_hospital | peri_urban | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 0 | 1 | 1 | unknown | 2,021 | 2 | pass | compliant | not_applicable | 96.4 | 0 | 0 | 0 | adult_male | 70 |
78 | national_programme | ARV_0123 | community_health_post | peri_urban | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 1 | 1 | 0 | unknown | 2,022 | 1 | pass | compliant | not_applicable | 101.7 | 0 | 0 | 0 | adult_male | 12 |
79 | national_programme | ARV_0008 | private_pharmacy | rural | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 1 | 1 | 0 | India | 2,022 | 4 | pass | compliant | not_applicable | 99 | 0 | 0 | 0 | adolescent | 51 |
80 | national_programme | ARV_0167 | ART_clinic | peri_urban | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 1 | 1 | 1 | India | 2,024 | 4 | pass | compliant | not_applicable | 100 | 0 | 0 | 0 | adult_female | 15 |
81 | national_programme | ARV_0106 | ART_clinic | rural | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 0 | 1 | 1 | India | 2,024 | 3 | pass | compliant | not_applicable | 97.6 | 0 | 0 | 0 | adult_female | 120 |
82 | national_programme | ARV_0131 | private_pharmacy | rural | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 1 | 0 | 1 | South_Africa | 2,020 | 3 | pass | compliant | not_applicable | 98.5 | 0 | 0 | 0 | adult_male | 17 |
83 | national_programme | ARV_0159 | ART_clinic | peri_urban | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 1 | 0 | 1 | local_SSA | 2,023 | 1 | pass | compliant | not_applicable | 96.2 | 0 | 0 | 0 | adult_female | 94 |
84 | national_programme | ARV_0105 | ART_clinic | peri_urban | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 0 | 1 | 1 | unknown | 2,024 | 2 | pass | compliant | not_applicable | 98.4 | 0 | 0 | 0 | pregnant_woman | 5 |
85 | national_programme | ARV_0072 | district_hospital | rural | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 1 | 1 | 0 | India | 2,024 | 4 | pass | compliant | not_applicable | 98.9 | 0 | 0 | 0 | adult_female | 11 |
86 | national_programme | ARV_0093 | ART_clinic | urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 0 | 1 | 0 | India | 2,022 | 2 | pass | compliant | not_applicable | 98 | 0 | 0 | 0 | paediatric | 12 |
87 | national_programme | ARV_0182 | ART_clinic | urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 1 | 1 | 0 | unknown | 2,021 | 3 | pass | compliant | not_applicable | 94.8 | 0 | 0 | 0 | adolescent | 35 |
88 | national_programme | ARV_0149 | private_clinic | urban | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 0 | 1 | 0 | India | 2,022 | 2 | pass | compliant | not_applicable | 101 | 0 | 0 | 0 | adult_female | 105 |
89 | national_programme | ARV_0169 | district_hospital | peri_urban | abacavir_lamivudine_paediatric | NRTI | paediatric | dispersible | 0.15 | 1 | 1 | 1 | India | 2,024 | 4 | pass | compliant | not_applicable | 97.1 | 0 | 0 | 0 | adolescent | 61 |
90 | national_programme | ARV_0199 | private_pharmacy | peri_urban | nevirapine_suspension | NNRTI | paediatric | suspension | 0.08 | 1 | 1 | 0 | India | 2,022 | 4 | pass | compliant | not_applicable | 98.7 | 0 | 0 | 0 | adult_male | 111 |
91 | national_programme | ARV_0058 | ART_clinic | urban | dolutegravir_10mg_dispersible | INSTI | paediatric | dispersible | 0.18 | 1 | 1 | 0 | India | 2,024 | 4 | pass | compliant | not_applicable | 98.5 | 0 | 0 | 0 | adolescent | 16 |
92 | national_programme | ARV_0189 | community_health_post | peri_urban | darunavir_ritonavir | PI_based | third_line | tablet | 0.8 | 0 | 0 | 1 | India | 2,024 | 1 | pass | compliant | not_applicable | 99.2 | 0 | 0 | 0 | pregnant_woman | 5 |
93 | national_programme | ARV_0142 | ART_clinic | peri_urban | zidovudine_lamivudine | NRTI | legacy | tablet | 0.06 | 0 | 1 | 0 | local_SSA | 2,024 | 4 | pass | compliant | not_applicable | 98.9 | 0 | 0 | 0 | adult_male | 14 |
94 | national_programme | ARV_0060 | community_health_post | urban | cotrimoxazole_prophylaxis | OI_prophylaxis | prophylaxis | tablet | 0.01 | 0 | 1 | 0 | China | 2,024 | 2 | pass | compliant | not_applicable | 100.7 | 0 | 0 | 0 | pregnant_woman | 106 |
95 | national_programme | ARV_0034 | private_pharmacy | urban | fluconazole_200mg | OI_treatment | OI_treatment | capsule | 0.05 | 0 | 1 | 1 | India | 2,020 | 2 | pass | compliant | not_applicable | 99 | 0 | 0 | 0 | adult_female | 62 |
96 | national_programme | ARV_0020 | private_clinic | rural | isoniazid_300mg_TPT | TB_preventive | TPT | tablet | 0.02 | 1 | 1 | 0 | China | 2,023 | 1 | pass | compliant | not_applicable | 101.8 | 0 | 0 | 0 | adult_female | 49 |
97 | national_programme | ARV_0117 | private_pharmacy | peri_urban | TLD_tenofovir_lamivudine_dolutegravir | INSTI_based | first_line | tablet | 0.12 | 0 | 1 | 1 | India | 2,021 | 2 | pass | compliant | not_applicable | 100.4 | 0 | 0 | 0 | adult_male | 8 |
98 | national_programme | ARV_0033 | private_pharmacy | urban | TEE_tenofovir_lamivudine_efavirenz | NNRTI_based | first_line_legacy | tablet | 0.08 | 0 | 1 | 0 | India | 2,022 | 1 | pass | compliant | not_applicable | 101.9 | 0 | 0 | 0 | paediatric | 11 |
99 | national_programme | ARV_0123 | private_clinic | urban | atazanavir_ritonavir | PI_based | second_line | tablet | 0.25 | 0 | 1 | 0 | China | 2,024 | 1 | fail | falsified | counterfeit_packaging | 65.9 | 0 | 0 | 0 | paediatric | 15 |
100 | national_programme | ARV_0032 | district_hospital | peri_urban | lopinavir_ritonavir | PI_based | second_line | tablet | 0.2 | 1 | 1 | 0 | India | 2,020 | 2 | pass | compliant | not_applicable | 98.4 | 0 | 0 | 0 | adult_female | 19 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.